Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124468 | 0.92 | ELANE (0.64) | ELANECYP3A4CYP2C9 | |
| SCHEMBL124469 | 0.92 | ELANE (0.63) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8008373 | 0.90 | ELANE (0.65) | ELANECYP3A4CYP2C9 | |
| SCHEMBL12858960 | 0.90 | ELANE (0.70) | ELANE | |
| SCHEMBL13254814 | 0.88 | ELANE (0.78) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8011032 | 0.88 | ELANE (0.64) | ELANECYP3A4CYP2C9 | |
| SCHEMBL123912 | 0.87 | ELANE (0.69) | ELANECYP3A4CYP2C9 | |
| SCHEMBL125091 | 0.87 | ELANE (0.69) | ELANE | |
| SCHEMBL125604 | 0.87 | ELANE (0.69) | ELANECYP3A4CYP2C9 | |
| SCHEMBL121948 | 0.87 | ELANE (0.69) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-8288402-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288402-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | ELANE 1598/4885CYP3A4 199/4885CYP2C9 582/4885 |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | TNNI3, TNNT2, PC | ELANE 1850/4885CYP3A4 192/4885CYP2C9 581/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | ELANE 1598/4885CYP3A4 199/4885CYP2C9 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.